Advertisement

Drugs & Aging

, Volume 27, Issue 4, pp 265–282 | Cite as

General Anaesthesia in Elderly Patients with Cardiovascular Disorders

Choice of Anaesthetic Agent
  • Sangeeta Das
  • Kirsty ForrestEmail author
  • Simon Howell
Therapy In Practice

Abstract

Our population is aging; currently 15% of the Western population are aged >65 years, and represent 25% of those undergoing surgery. The proportion of the population aged ≥65 years is rapidly growing, and an increasing number are affected with cardiovascular disease.

The older person is a high-risk patient. This is because of their altered physiology and associated co-morbidities, as well as the pharmacokinetic and pharmacodynamic changes that may alter drug responses. There is considerable variability seen in the physical and physiological states of individual patients within the older population. This has an important impact on choosing a safe anaesthetic technique for each individual, which in turn can influence the morbidity and mortality in this population.

The physiological changes in the aging cardiovascular system affect the arterial and venous vasculature, myocardium and autonomic nervous system, making the older person more prone to cardiovascular instability. In addition to the physiological changes, the cardiovascular status of the older person tends to be compromised by associated pathological conditions that are more common with increasing age. Pharmacokinetic and pharmacodynamic changes must be taken into account when deciding about drug dosing in this age group. Aspects of dose reduction, titration of drugs, dosing intervals and the pharmacodynamic effects of each class of drug are explained in detail in the text.

The major challenge in anaesthesia for the older person with cardiovascular disease is maintenance of haemodynamic stability, particularly in the face of reduced physiological reserve and capability to respond to periods of instability. An appropriate anaesthetic technique must be selected to minimize haemodynamic changes and maintain near normal physiological status. The other key objective is to minimize the incidence of adverse outcomes, such as perioperative myocardial ischaemia/infarction, arrhythmias, heart failure, postoperative cognitive dysfunction and stroke. No single anaesthetic regimen or agent can be advocated. Knowledge of the pharmacokinetic and pharmacodynamic principles of anaesthetic agents and their altered response in elderly patients is essential when selecting an anaesthetic agent.

This article provides a practical guide to the selection and use of general anaesthetic agents in older patients with cardiovascular disorders, highlighting the differences among various agents.

Keywords

Midazolam Sevoflurane Remifentanil Anaesthetic Agent Thiopentone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this article. All authors made substantial contributions to the planning, writing and reviewing of the article. The authors would like to acknowledge Dr Nicola Cooper and Dr Alison Cracknell for comments on the manuscript.

References

  1. 1.
    Priebe HJ. The aged cardiovascular risk patient. Br J Anaesth 2000; 85: 763–78PubMedCrossRefGoogle Scholar
  2. 2.
    Friedl LP, Kronmal RA, Newman AB, et al. Risk factors for five year mortality in older adults: the Cardiovascular Health Study. JAMA 1998; 279: 585–92CrossRefGoogle Scholar
  3. 3.
    Hall WJ. Update in geriatrics. Ann Intern Med 1997; 127: 557–64PubMedGoogle Scholar
  4. 4.
    Shipton EA. The perioperative care of the geriatric patient. S Afr Med J 1983; 63: 855–60PubMedGoogle Scholar
  5. 5.
    Help the aged: we will. Facts and figures [online]. Available from URL: http://www.helptheaged.org.uk/en-gb/WhatWeDo/FactsAndFigures/FactsAndFigures/ [Accessed 2009 Feb 1]
  6. 6.
    Rooke GA. Cardiovascular ageing and anesthetic implications. J Cardiothorac Vasc Anesth 2003; 17(4): 512–23PubMedCrossRefGoogle Scholar
  7. 7.
    Lichtor JL. Sponsored research reveals postoperative mortality stats. Anesth Patient Saf Found Newsl 1988; 3: 9–11Google Scholar
  8. 8.
    Khuri SF, Daley J, Henderson W, et al. Risk adjustment of postoperative mortality rate for the comparative assessment of the quality of surgical care: results of the National Veterans Affairs Surgical Risk Study. J Am Coll Surg 1997; 185: 315–27PubMedGoogle Scholar
  9. 9.
    Groenink M, Langerak SE, Vanbavel E, et al. The influence of ageing and aortic stiffness on permanent dilation and breaking stress of the thoracic descending aorta. Cardiovasc Res 1999; 43: 471–80PubMedCrossRefGoogle Scholar
  10. 10.
    Lakatta E. Ageing effects on the vasculature in health: risk factors for cardiovascular disease. Am J Geriatr Cardiol 1994; 3: 11–7PubMedGoogle Scholar
  11. 11.
    Lakatta EG. Cardiovascular ageing research: the next horizons. J Am Geriatr Soc 1999; 47: 613–25PubMedGoogle Scholar
  12. 12.
    Bulpitt CJ, Rajkumar C, Cameron JD. Vascular compliance as a measure of biological age. J Am Geriatr Soc 1999; 47: 657–63PubMedGoogle Scholar
  13. 13.
    Yin FCP, Ting CT. Compliance changes in physiological and pathological states. J Hypertension 1992; 10 Suppl.: 31–3CrossRefGoogle Scholar
  14. 14.
    Downes TR, Nomeir AB, Smith KM, et al. Mechanism of altered pattern of left ventricular filling with ageing in subjects without cardiac disease. Am J Cardiol 1989; 64: 523–7PubMedCrossRefGoogle Scholar
  15. 15.
    Ebert TJ, Morgan BJ, Barney JA, et al. Effects of ageing on baroreflex regulation of sympathetic activity in humans. Am J Physiol 1992; 263: H798–803PubMedGoogle Scholar
  16. 16.
    Lakatta EG. Alteration in the cardiovascular system that occur in advanced age. Fed Proc 1979; 38: 13–167Google Scholar
  17. 17.
    Fagard R, Thijs L, Amery A. Age and the hemodynamic response to posture and to exercise. Am J Geriatr Cardiol 1993; 2: 23–40PubMedGoogle Scholar
  18. 18.
    Gribbin B, Pickering TG, Sleight P, et al. Effect of age and high blood pressure on baroreflex sensitivity in man. Circ Res 1971; 29: 424–31PubMedCrossRefGoogle Scholar
  19. 19.
    Critchley LAH, Conway F. Hypotension during subarachnoid anaesthesia: haemodynamic effects of colloid and metaraminol. Br J Anaesth 1996; 76: 734–6PubMedCrossRefGoogle Scholar
  20. 20.
    Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. Executive summary: report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2007; 50: 1707–32PubMedCrossRefGoogle Scholar
  21. 21.
    Shah KB, Kleinman BS, Sami H, et al. Re-evaluation of perioperative myocardial infarction in patients with prior myocardial infarction undergoing noncardiac operations. Anesth Analg 1990; 71: 231–5PubMedCrossRefGoogle Scholar
  22. 22.
    Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac risk in noncardiac surgical procedures. N Engl J Med 1977; 297: 845–50PubMedCrossRefGoogle Scholar
  23. 23.
    Howell SJ, Sear YM, Sear JW, et al. Cardiovascular death within 30 days following anaesthesia and urgent or emergency surgery: determination of risk factors using a nested case control study. Br J Anaesth 1999; 82: 679–84PubMedCrossRefGoogle Scholar
  24. 24.
    Levine WC, Mehta V, Landesberg G, et al. Anaesthesia for elderly: selected topics. Curr Opin Anaesthesiol 2006; 19: 320–4PubMedCrossRefGoogle Scholar
  25. 25.
    Hart CY, Redfield MM. Diastolic heart failure in the community. Curr Cardiol Rep 2000; 2: 461–9PubMedCrossRefGoogle Scholar
  26. 26.
    Howell SJ, Sear JW, Foex P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 2004; 92(4): 570–83PubMedCrossRefGoogle Scholar
  27. 27.
    Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354–60PubMedCrossRefGoogle Scholar
  28. 28.
    Williams B, Poulter NR, Brown MJ, et al. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV). BMJ 2004; 328: 634–40PubMedCrossRefGoogle Scholar
  29. 29.
    Aronson S, Boisvert D, Lapp W. Isolated systolic hypertension is associated with adverse outcomes from coronary artery bypass grafting surgery. Anesth Analg 2002; 94: 1079–84PubMedCrossRefGoogle Scholar
  30. 30.
    Podrid PJ. Atrial fibrillation in the elderly. Cardiol Clin 1999; 17: 173–88PubMedCrossRefGoogle Scholar
  31. 31.
    Christ M, Sharkova Y, Geldner G, et al. Preoperative and perioperative care for patients with suspected or established aortic stenosis facing noncardiac surgery. Chest 2005; 128: 2944–53PubMedCrossRefGoogle Scholar
  32. 32.
    Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630–4PubMedCrossRefGoogle Scholar
  33. 33.
    Lindroos M, Kupari M, Heikkila J, et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 1993; 21: 1220–5PubMedCrossRefGoogle Scholar
  34. 34.
    Lombard JT, Selzer A. Valvular aortic stenosis: a clinical and hemodynamic profile of patients. Ann Intern Med 1987; 106: 292–8PubMedGoogle Scholar
  35. 35.
    Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery. Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg 2002; 94: 1052–64PubMedCrossRefGoogle Scholar
  36. 36.
    Cooper N, Forrest K, Mulley G, editors. ABC of geriatric medicine. Oxford: Wiley-Blackwell, 2009 JanGoogle Scholar
  37. 37.
    Comfere T, Sprung J, Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. Anesth Analg 2005; 100: 636–44PubMedCrossRefGoogle Scholar
  38. 38.
    Mangano DT, Layug EL, Wallace A, et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery: Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713–20PubMedCrossRefGoogle Scholar
  39. 39.
    Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery: Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789–94PubMedCrossRefGoogle Scholar
  40. 40.
    POISE study group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008; 371: 1839–47CrossRefGoogle Scholar
  41. 41.
    Poldermans D, Schouten O, Van Lier F, et al. Perioperative strokes and β-blockade. Anesthesiology 2009; 111: 940–5PubMedCrossRefGoogle Scholar
  42. 42.
    Hayashi Y, Sumikawa K, Kuro M, et al. Rolls of beta 1 and beta 2 adrenoceptors in the mechanism of halothane myocardial sensitization in dogs. Anesth Analg 1991; 72(4): 435–9PubMedCrossRefGoogle Scholar
  43. 43.
    Wood M. Pharmacokinetic drug interactions in anaesthetic practice. Clin Pharmacokinet 1991; 21(4): 285–304PubMedCrossRefGoogle Scholar
  44. 44.
    Wali FA. Interaction of verapamil with gallamine and pancuronium and reversal of combined neuromuscular blockade with neostigmine and edrophonium. Eur J Anaesthesiol 1986; 3(5): 385–93PubMedGoogle Scholar
  45. 45.
    Dec GW. Digoxin remains useful in the treatment of chronic heart failure. Med Clin North Am 2003; 87(2): 317–37PubMedCrossRefGoogle Scholar
  46. 46.
    Bartolone RS, Rao TL. Dysrhythmias following muscle relaxant administration in patients receiving digitalis. Anesthesiology 1983; 58(6): 567–9PubMedCrossRefGoogle Scholar
  47. 47.
    Stoelting RK. Pharmacology and physiology in anesthetic practice. 3rd ed. Philadelphia (PA): Lippincott-Raven, 1999Google Scholar
  48. 48.
    Silverstein JH, Rooke GA, Reves JG, et al. Geriatric anaesthesiology. 2nd ed. New York: Springer Science and Business Media, 2008CrossRefGoogle Scholar
  49. 49.
    Martin G, Glass PS, Breslin DS, et al. A study of anesthetic drug utilisation in different age groups. J Clin Anesth 2003; 15(3); 194–200PubMedCrossRefGoogle Scholar
  50. 50.
    Kirkbride DA, Parker JL, Williams GD, et al. Induction of anesthesia in the elderly ambulatory patients: a double blinded comparison of propofol and sevoflurane. Anesth Analg 2001; 93(5): 1185–7PubMedCrossRefGoogle Scholar
  51. 51.
    John AD, Sieber FE. Age associated issues: geriatrics. Anesthesiol Clin North Am 2004; 22(1): 45–58CrossRefGoogle Scholar
  52. 52.
    Shafer SL. The pharmacology of anaesthetic drugs in elderly patients. Anesthesiol Clin North Am 2000; 18(1): 1–29CrossRefGoogle Scholar
  53. 53.
    Scheepstra GL, Booij LH, Rutten CL, et al. Propofol for induction and maintenance of anaesthesia: comparison between older and younger patients. Br J Anaesth 1989; 62: 54–60PubMedCrossRefGoogle Scholar
  54. 54.
    Kazama T, Ikeda K, Morita K, et al. Comparison of the effect site k(e0)s of propofol for blood pressure and EEG by spectral index in elderly and younger patients. Anesthesiology 1999; 90(6): 1517–27PubMedCrossRefGoogle Scholar
  55. 55.
    Schuttler J, Ihmsen H. Population pharmacokinetics of propofol: a multicenter study. Anesthesiology 2000; 92: 727–38PubMedCrossRefGoogle Scholar
  56. 56.
    Schnider TW, Minto CF, Gumbus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 1998; 88(5): 1170–82PubMedCrossRefGoogle Scholar
  57. 57.
    Schnider TW, Minto CF, Shafer SL, et al. The influence of age on propofol pharmacodynamics. Anesthesiology 1999; 90: 1502–16PubMedCrossRefGoogle Scholar
  58. 58.
    Russo H, Bressolle E. Pharmacokinetics and pharmacodynamics of thiopental. Clin Pharmacokinet 1998; 35: 95–134PubMedCrossRefGoogle Scholar
  59. 59.
    Ball C, Westhorpe R. The history of intravenous anaesthesia: the barbiturates. Part 1. Anaesth Intensive Care 2001; 29(2): 97Google Scholar
  60. 60.
    Ball C, Westhorpe R. The history of intravenous anaesthesia: the barbiturates. Part 2. Anaesth Intensive Care 2001; 29(3): 219Google Scholar
  61. 61.
    Ball C, Westhorpe R. The history of intravenous anaesthesia: the barbiturates. Part 3. Anaesth Intensive Care 2001; 29(4): 323Google Scholar
  62. 62.
    Dundee JW. Fifty years of thiopentone [editorial]. Br J Anaesth 1984; 56: 211PubMedCrossRefGoogle Scholar
  63. 63.
    Sonntag H, Hellberg K, Schenk HD, et al. Effects of thiopental (Trapanal) on coronary blood flow and myocardial metabolism in man. Acta Anesthesiol Scand 1975; 19(1): 69–78CrossRefGoogle Scholar
  64. 64.
    Homer TD, Stanski DR. The effect of increasing age on thiopental disposition and anesthetic requirement. Anesthesiology 1985; 62: 714–24PubMedCrossRefGoogle Scholar
  65. 65.
    Stanski DR, Maitre PO. Population pharmacokinetics and pharmacodynamics of thiopental: the effect of age revisited. Anesthesiology 1990; 72: 412–22PubMedCrossRefGoogle Scholar
  66. 66.
    Dundee JW, Halliday NJ, Loughran PG, et al. The influence of age on the onset of anaesthesia with midazolam. Anaesthesia 1985; 40: 441–3PubMedCrossRefGoogle Scholar
  67. 67.
    White PF, Negus JB. Sedative infusions during local and regional anesthesia: a comparison of midazolam and propofol. J Clin Anesth 1991; 3(1): 32–9PubMedCrossRefGoogle Scholar
  68. 68.
    Sunzel M, Pallzow L, Berggren L, et al. Respiratory and cardiovascular effects in relation to plasma levels of midazolam and diazepam. Br J Clin Pharmacol 1988; 25: 561–9PubMedCrossRefGoogle Scholar
  69. 69.
    Samuelson PN, Reves JG, Kouchoukos NT, et al. Hemodynamic responses to anesthetic induction with midazolam or diazepam in patients with ischemic disease. Anesth Analg 1981; 60: 802–9PubMedCrossRefGoogle Scholar
  70. 70.
    Rouff R, Reves JG. Hemodynamic effects of lorazepam-fentanyl anesthetic induction for coronary artery bypass surgery. J Cardiothorac Anesth 1990; 4: 314–7CrossRefGoogle Scholar
  71. 71.
    Heikkilä H, Jalonen J, Arola M, et al. Midazolam as adjunct to high-dose fentanyl anesthesia for coronary artery bypass graft operation. Acta Anaesthesiol Scand 1984; 28: 683–9PubMedCrossRefGoogle Scholar
  72. 72.
    Benson KT, Tomlinson DL, Goto H, et al. Cardiovascular effects of lorazepam during sufentanil anesthesia. Anesth Analg 1988; 67: 966–8CrossRefGoogle Scholar
  73. 73.
    Windsor JW, Sherry K, Feneck RO, et al. Sufentanil and nitrous oxide anesthesia for cardiac surgery. Br J Anaesth 1988; 61: 662–8PubMedCrossRefGoogle Scholar
  74. 74.
    Maitre PO, Buhrer M, Thomson D, et al. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm 1991; 19: 377–84PubMedGoogle Scholar
  75. 75.
    Reves JG, Fragen RJ, Vinik HR, et al. Midazolam: pharmacology and uses. Anesthesiology 1985; 62: 310–24PubMedCrossRefGoogle Scholar
  76. 76.
    Allolio B, Dorr H, Stuttmann R, et al. Effect of a single bolus dose of etomidate upon eight major corticosteroid hormones and plasma ACTH. Clin Endocrinol (Oxf) 1985; 22: 281–6CrossRefGoogle Scholar
  77. 77.
    Holdcroft A, Morgan M, Whitwam JG, et al. Effect of dose and premedication on induction complications with etomidate. Br J Anaesth 1976; 48: 199–205PubMedCrossRefGoogle Scholar
  78. 78.
    Kettler D, Sonnata H, Donath U, et al. Haemodynamics, myocardial mechanics, oxygen requirement and oxygenation of the human heart during induction of anaesthesia with etomidate [in German]. Anaesthesist 1974; 23: 116–21PubMedGoogle Scholar
  79. 79.
    Arden JR, Holley OF, Stanski DR. Increased sensitivity to etomidate in the elderly: initial distribution versus altered brain response. Anesthesiology 1986; 65: 19–27PubMedCrossRefGoogle Scholar
  80. 80.
    Calvey TN, Williams NE. Principles and practice of pharmacology for anaesthetists. 4th ed. Oxford: Blackwell Scientific Publications, 2001Google Scholar
  81. 81.
    Jolly AS, Jain P, Sood J. Ketamine: current uses and future perspectives. J Anaesthesiol Clin Pharmacol 2007; 23(2): 169–81Google Scholar
  82. 82.
    Granry JC, Dube L, Turroques H, et al. Ketamine: new uses for an old drug. Curr Opin Anaesthesiol 2000; 13(3): 299–302PubMedCrossRefGoogle Scholar
  83. 83.
    Finlay I. Ketamine and its role in cancer pain. Pain Rev 1999; 6(4): 303–13CrossRefGoogle Scholar
  84. 84.
    Maneglia R, Cousin MT. A comparison between propofol and ketamine for anaesthesia in the elderly: haemodynamic effects during induction and maintenance. Anaesthesia 1988; 43 Suppl.: 109–11PubMedCrossRefGoogle Scholar
  85. 85.
    Zickmann B, Kling D, Quis S. S-(+)-ketamine versus ketamine racemic mixture: hemodynamic studies. Anasthesiol Intensivmed Notfallmed Schmerzther 2000; 35(5): 333–9PubMedCrossRefGoogle Scholar
  86. 86.
    Adams HA. S-(+)-ketamine: cardiovascular interactions during total intravenous anaesthesia and analgosedation. Anaesthesist 1997; 46(12): 1081–7PubMedCrossRefGoogle Scholar
  87. 87.
    Pai A, Heining M. Ketamine. Cont Educ Anaesth Crit Care Pain (CEACCP) 2007; 7: 59–63CrossRefGoogle Scholar
  88. 88.
    Miller RD. Miller’s anesthesia. 7th ed. Edinburgh: Elsevier Churchill Livingstone, 2009Google Scholar
  89. 89.
    Hudetz JA, Iqbal Z, Gandhi SD, et al. Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. Acta Anaesthesiol Scand 2009; 53(7): 864–72PubMedCrossRefGoogle Scholar
  90. 90.
    Himmelseher S, Pfenninger E. The clinical use of S-(+)-ketamine: a determination of its place. Anasthesiol Intensivmed Notfallmed Schmerzther 1998; 33(12): 764–70PubMedCrossRefGoogle Scholar
  91. 91.
    Houltz E, Caidahl K, Adin C, et al. Effects of halo thane and isoflurane on left ventricular diastolic function during surgical stress in patients with coronary artery disease. Acta Anaesthesiol Scand 1996; 41: 931–8CrossRefGoogle Scholar
  92. 92.
    McKinney MS, Fee JP, Clarke RS. Cardiovascular effects of isoflurane and halothane in young and elderly patients. Br J Anaesth 1993; 71: 696–701PubMedCrossRefGoogle Scholar
  93. 93.
    Malan TP, Dinardo JA, Isner RJ, et al. Cardiovascular effects of sevoflurane compared with those of isoflurane in volunteers. Anesthesiology 1995; 83: 918–28PubMedCrossRefGoogle Scholar
  94. 94.
    Yamaguchi S, Ikeda T, Wake K, et al. A sevoflurane induction of anaesthesia with gradual reduction of concentration is well tolerated in elderly patients. Can J Anesth 2003; 50: 26–31PubMedCrossRefGoogle Scholar
  95. 95.
    Weiskopef RB, Moore MA, Eger II EI, et al. Rapid increase in desflurane concentration is associated with greater transient cardiovascular stimulation than with rapid increase in isoflurane concentration in humans. Anesthesiology 1994; 80: 1035–45CrossRefGoogle Scholar
  96. 96.
    Mapleson WW. Effect of age on MAC in humans: a metaanalysis. Br J Anaesth 1996; 76: 179–85PubMedCrossRefGoogle Scholar
  97. 97.
    Cepeda MS, Farrar JT, Baumgarten M, et al. Side effects of opioids during short term administration: effect of age, gender and race. Clin Pharmacol Ther 2003; 74: 102–12PubMedCrossRefGoogle Scholar
  98. 98.
    Sinclair DR, Chung F, Mezei G. Can postoperative nausea and vomiting be predicted? Anesthesiology 1999; 91: 109–18PubMedCrossRefGoogle Scholar
  99. 99.
    Portenoy RK, Foley KM, Stulman J, et al. Plasma morphine and morphine-6-glucuronide during chronic morphine therapy for cancer pain: plasma profiles, steady state concentrations and the consequences of renal failure. Pain 1991; 47: 13–9PubMedCrossRefGoogle Scholar
  100. 100.
    Lotsch J, Skarke C, Schmidt H, et al. The transfer half life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers. Anesthesiology 2001; 95: 1329–38PubMedCrossRefGoogle Scholar
  101. 101.
    Skarke C, Jarrar M, Erb K, et al. Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine. Clin Pharmacol Ther 2003; 74: 303–11PubMedCrossRefGoogle Scholar
  102. 102.
    Skarke C, Darimont J, Schmidt H, et al. Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin Pharmacol Ther 2003; 73: 107–21PubMedCrossRefGoogle Scholar
  103. 103.
    Aubrun F, Monsel S, Langeron O, et al. Post operative titration of intravenous morphine in the elderly patient. Anesthesiology 2002; 96: 17–23PubMedCrossRefGoogle Scholar
  104. 104.
    Auburn F, Bunge D, Langeron O, et al. Postoperative morphine consumption in the elderly patient. Anesthesiology 2003; 99: 160–5CrossRefGoogle Scholar
  105. 105.
    Homburger JA, Meiler SE. Anesthesia drugs, immunity and long term outcome. Curr Opin Anaesthesiol 2006; 19(4): 423–8PubMedCrossRefGoogle Scholar
  106. 106.
    Welters I. Opioids and immunosuppression: clinical relevance? Anaesthesist 2003; 52(5): 442–52PubMedCrossRefGoogle Scholar
  107. 107.
    Scott JC, Stanski DR. Decreased fentanyl/alfentanil dose requirement with increasing age: a pharmacodynamic basis. J Pharmacol Exp Ther 1987; 240: 159–66PubMedGoogle Scholar
  108. 108.
    Scott JC, Ponganis KV, Stanski DR. EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 1985; 62: 234–41PubMedCrossRefGoogle Scholar
  109. 109.
    Minto CF, Schnider TW, Shafer SL. The influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. II: model application. Anesthesiology 1997; 86: 24–33PubMedCrossRefGoogle Scholar
  110. 110.
    Duvaldestin P, Saada J, Berger JL, et al. Pharmacokinetics, pharmacodynamics and dose-response relationships of pancuronium in control and elderly subjects. Anesthesiology 1982; 56: 36–40PubMedCrossRefGoogle Scholar
  111. 111.
    Edward Morgan G. Clinical anesthesiology. 3rd ed. New York: Lange Medical Books/Mcgraw-Hill Medical Publishing, 2002Google Scholar
  112. 112.
    Kitts JB, Fisher DM, Canfell PC, et al. Pharmacokinetics and pharmacodynamics of atracurium in the elderly. Anesthesiology 1990; 72: 272–5PubMedCrossRefGoogle Scholar
  113. 113.
    Parker CJ, Hunter JM, Snowdon SL. Effect of age, gender and anaesthetic technique on the pharmacodynamics of atracurium. Br J Anaesth 1993; 70: 38–41PubMedCrossRefGoogle Scholar
  114. 114.
    Rupp SM, Castagnoli KP, Fisher DM, et al. Pancuronium and vecuronium pharmacokinetics and pharmacodynamics in younger and elderly adults. Anesthesiology 1987; 67: 45–9PubMedCrossRefGoogle Scholar
  115. 115.
    d’Hollander AA, Massaux F, Nevelsteen M, et al. Age dependent dose-response relationship of ORG NC45 in anaesthetised patients. Br J Anaesth 1982; 54: 653–6PubMedCrossRefGoogle Scholar
  116. 116.
    Hunter JM. New neuromuscular blocking agents. N Engl J Med 1995; 332(25): 1691–9PubMedCrossRefGoogle Scholar
  117. 117.
    Baykara N, Solak M, Toker K. Predicting recovery from deep neuromuscular block by rocuronium in the elderly. J Clin Anesth 2003; 15: 328–33PubMedCrossRefGoogle Scholar
  118. 118.
    Bevan DR, Fiset P, Balendran P, et al. Pharmacodynamic behaviour of rocuronium in the elderly. Can J Anesth 1993; 40: 127–32PubMedCrossRefGoogle Scholar
  119. 119.
    Matteo RS, Ornstein E, Schwartz AE, et al. Pharmacokinetics and pharmacodynamics of rocuronium in elderly surgical patients. Anesth Analg 1993; 77: 1193–7PubMedCrossRefGoogle Scholar
  120. 120.
    Shorten GD, Uppington J, Comunale ME. Changes in plasma catecholamine concentrations and haemodynamic effects of rocuronium and vecuronium in elderly patients. Eur J Anaesthesiol 1998; 15(3): 335–41PubMedGoogle Scholar
  121. 121.
    Cope TM, Hunter JM. Selecting neuromuscular-blocking drugs for elderly patients. Drugs Aging 2003; 20(2): 125–40PubMedCrossRefGoogle Scholar
  122. 122.
    Maddineni VR, Mirakhur RK, McCoy EP. Plasma cholinesterase activity in elderly and young adults [letter]. Br J Anaesth 1994; 72: 497PubMedCrossRefGoogle Scholar
  123. 123.
    Viby-Mogensen J. Correlation of succinylcholine duration of action with plasma cholinesterase activity in subjects with the genotypically normal enzyme. Anesthesiology 1980; 53: 517–20PubMedCrossRefGoogle Scholar
  124. 124.
    GlaxoSmithKline UK. Medicine guide for Anectine (suxamethonium chloride) 2008 Oct [online]. Available from URL: http://www.gsk.com/products/prescription-medicines/anectine.htm [Accessed 2009 Feb 1]
  125. 125.
    Koscielniak-Nielsen ZJ, Law-Min JC, Donati F, et al. Dose-response relations of doxacurim and its reversal with neostigmine in young adults and healthy elderly patients. Anaesth Analg 1992; 74: 845–50CrossRefGoogle Scholar
  126. 126.
    Young WL, Matteo RS, Ornstein E. Duration of action of neostigmine and pyridostigmine in the elderly. Anesth Analg 1988; 67: 775–8PubMedGoogle Scholar
  127. 127.
    Young WL, Backus W, Matteo RS, et al. Pharmacokinetics and pharmacodynamics of neostigmine in the elderly [abstract]. Anesthesiology 1984; 61: A300CrossRefGoogle Scholar
  128. 128.
    Muravchick S, Owens WD, Felts JA. Glycopyrrolate and cardiac dysrhythmias in geriatric patients after reversal of neuromuscular blockade. Can Anaesth Soc J 1979; 26: 22–5PubMedCrossRefGoogle Scholar
  129. 129.
    Caldwell JE, Miller RD. Clinical implications of sugammadex. Anaesthesia 2009; 64Suppl. 1: 66–72PubMedCrossRefGoogle Scholar
  130. 130.
    Yang LP, Keam SJ. Sugammadex: a review of its use in anaesthetic practice. Drugs 2009; 69(7): 919–42PubMedCrossRefGoogle Scholar
  131. 131.
    Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesthesia Analg 2007; 104(3): 575–81CrossRefGoogle Scholar
  132. 132.
    Poldermans D, Jeroen JB, Boersma E, et al. Task Force of European Society of Cardiology (endorsed by the European Society of Anaesthesiology). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769–812PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Department of Anaesthesia, Leeds Teaching Hospital TrustThe General Infirmary at LeedsLeedsUK
  2. 2.Academic Unit of AnaesthesiaThe General Infirmary at LeedsLeedsUK

Personalised recommendations